158 related articles for article (PubMed ID: 38358393)
21. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
22. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Allen C; Fangusaro J; Hutter C; Witt O; Weiner S; Reaman G; Russo M; Bandopadhayay P; Ahsan S; Barone A; Barry E; de Rojas T; Fisher M; Fox E; Bender JG; Gore L; Hargrave D; Hawkins D; Kreider B; Langseth AJ; Lesa G; Ligas F; Marotti M; Marshall LV; Nasri K; Norga K; Nysom K; Pappo A; Rossato G; Scobie N; Smith M; Stieglitz E; Weigel B; Weinstein A; Viana R; Karres D; Vassal G
Eur J Cancer; 2022 Dec; 177():120-142. PubMed ID: 36335782
[TBL] [Abstract][Full Text] [Related]
23. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
24. Tovorafenib (Ojemda) for pediatric low-grade glioma.
Med Lett Drugs Ther; 2024 Jun; 66(1704):e97-e98. PubMed ID: 38905536
[No Abstract] [Full Text] [Related]
25. Tailoring chemotherapy for low-grade gliomas.
Galanis E
Oncology (Williston Park); 2014 Dec; 28(12):1052, 1071. PubMed ID: 25510805
[No Abstract] [Full Text] [Related]
26. Neuropsychological impact of trametinib in pediatric low-grade glioma: A case series.
Peterson RK; McKeown T; Tabori U; Bartels U; Bouffet E; Janzen L
Pediatr Blood Cancer; 2020 Dec; 67(12):e28690. PubMed ID: 32930446
[TBL] [Abstract][Full Text] [Related]
27. mTOR: a new therapeutic target for pediatric low-grade glioma?
Rodriguez FJ; Raabe EH
CNS Oncol; 2014 Mar; 3(2):89-91. PubMed ID: 25055011
[No Abstract] [Full Text] [Related]
28. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Guerreiro Stucklin A; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang S; Snuderl M; Nageswara Rao A; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Faure Conter C; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser P; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen S; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U
J Clin Oncol; 2017 Sep; 35(25):2934-2941. PubMed ID: 28727518
[TBL] [Abstract][Full Text] [Related]
29. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
Plant-Fox AS; O'Halloran K; Goldman S
Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
[TBL] [Abstract][Full Text] [Related]
30. EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations.
Boesen K; Gøtzsche PC; Ioannidis JPA
Epidemiol Psychiatr Sci; 2021 Apr; 30():e35. PubMed ID: 33926608
[TBL] [Abstract][Full Text] [Related]
31. Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities.
Haase S; Nuñez FM; Gauss JC; Thompson S; Brumley E; Lowenstein P; Castro MG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348922
[TBL] [Abstract][Full Text] [Related]
32. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop.
Huse JT; Wallace M; Aldape KD; Berger MS; Bettegowda C; Brat DJ; Cahill DP; Cloughesy T; Haas-Kogan DA; Marra M; Miller CR; Nelson SJ; Salama SR; Soffietti R; Wen PY; Yip S; Yen K; Costello JF; Chang S
Neuro Oncol; 2014 Jan; 16(2):173-8. PubMed ID: 24305708
[TBL] [Abstract][Full Text] [Related]
33. Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.
Erker C; Tamrazi B; Poussaint TY; Mueller S; Mata-Mbemba D; Franceschi E; Brandes AA; Rao A; Haworth KB; Wen PY; Goldman S; Vezina G; MacDonald TJ; Dunkel IJ; Morgan PS; Jaspan T; Prados MD; Warren KE
Lancet Oncol; 2020 Jun; 21(6):e317-e329. PubMed ID: 32502458
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas.
Greenberger BA; Pulsifer MB; Ebb DH; MacDonald SM; Jones RM; Butler WE; Huang MS; Marcus KJ; Oberg JA; Tarbell NJ; Yock TI
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1060-1068. PubMed ID: 25035209
[TBL] [Abstract][Full Text] [Related]
35. Surrogate Endpoints in Pediatric Studies Submitted to the US FDA.
Green DJ; Sun H; Burnham J; Liu XI; van den Anker J; Temeck J; Yao L; McCune SK; Burckart GJ
Clin Pharmacol Ther; 2019 Mar; 105(3):555-557. PubMed ID: 30094815
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab for the treatment of high-grade glioma.
Khasraw M; Simeonovic M; Grommes C
Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
[TBL] [Abstract][Full Text] [Related]
37. Steps toward harmonization for clinical development of medicines in pediatric ulcerative colitis-a global scientific discussion, part 1: efficacy endpoints and disease outcome assessments.
Sun H; Vesely R; Taminiau J; Szitanyi P; Papadopoulos EJ; Isaac M; Klein A; Uzu S; Griebel D; Mulberg AE;
J Pediatr Gastroenterol Nutr; 2014 Jun; 58(6):679-83. PubMed ID: 24866781
[TBL] [Abstract][Full Text] [Related]
38. Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
Jaspan T; Morgan PS; Warmuth-Metz M; Sanchez Aliaga E; Warren D; Calmon R; Grill J; Hargrave D; Garcia J; Zahlmann G
AJNR Am J Neuroradiol; 2016 Sep; 37(9):1581-7. PubMed ID: 27127006
[TBL] [Abstract][Full Text] [Related]
39. Outcome selection for tissue-agnostic drug trials for immune-mediated inflammatory diseases: a systematic review of core outcome sets and regulatory guidance.
Aiyegbusi OL; di Ruffano LF; Retzer A; Newsome PN; Buckley CD; Calvert MJ
Trials; 2022 Jan; 23(1):42. PubMed ID: 35033186
[TBL] [Abstract][Full Text] [Related]
40. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.
Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK
J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
